Peer-reviewed preclinical melanoma research finds Provectus’s synthetic small molecule can both stimulate anti-tumor immunity and suppress ...
Every investor is looking for opportunities, but finding promising stocks and deciding when to buy is rarely a simple task. Successful investing often depends on separating temporary market moves from ...
Brii Bio announces positive end-of-treatment results from phase 2b ENRICH & ENHANCE studies to treat chronic hepatitis B: Durham, North Carolina Monday, July 6, 2026, 18:00 Hrs [I ...
Abstract: Tiny AI-edge devices use nvCIM for power-off weight storage and active-mode computation, enabling high energy efficiency (EF) and low power-on latency. While tiny Transformer models offer ...
Global hepatitis report 2024: action for access in low- and middle-income countries. World Health Organization. Retrieved from ...
Vietnam Investment Review on MSN
Brii Bio phase 2b hepatitis B data from ENRICH and ENHANCE studies released
DURHAM, N.C. and BEIJING, July 3, 2026 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient ...
Abstract: The current sequential recommendation systems mainly focus on mining information related to users to make personalized recommendations. However, there are two subjects in the user historical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results